@FierceMedDev: Alere's losses triple as investor fight awaits. Story | Results | Follow @FierceMedDev
@MarkHFierce: Italy's Sorin has finally recovered from earthquake-related earnings challenges. Story | Follow @MarkHFierce
@DamianFierce: Siemens: Löscher's out; Kaeser's in; revenue's still sagging. Much more here: Report | Follow @DamianFierce
> Life Technologies ($LIFE) has signed a deal with Novartis ($NVS), allowing the drugmaker to use its modified T cell technology for cancer treatments. News
> GE Healthcare ($GE) submitted the final portion of its FDA application for a new breast imaging technology that uses tomosynthesis to provide 3-D images. More
> Allergan ($AGN) reported $1.6 billion in sales last quarter, a 10.6% increase sped along by a strong performance from its medical device business, which grew 7.4% to $229.3 million. Results
> Roche Diagnostics ($RHHBY) has launched a new automation system for its Cobas 8100 analyzers. Release
> Teleflex ($TFX) posted $420.1 million in revenue last quarter, a 9.6% jump, while net income stayed about flat at $42.4 million. Financials
> Episurf Medical won a CE mark for a new implant designed to treat cartilage damage in the knee. Item
Biotech News
@FierceBiotech: From FierceBiotechIT.com: Ex-Yahoo CEO backs genomics big data startup Bina. Article | Follow @FierceBiotech
@JohnCFierce: AstraZeneca commits $815M to partner with FibroGen on anemia drug. News | Follow @JohnCFierce
@RyanMFierce: There are no drugs approved specifically for Fragile X, a top genetic cause of autism and intellectual disability. More | Follow @RyanMFierce
@EmilyMFierce: New compound could combat castration-resistant prostate cancer. Story | Follow @EmilyMFierce
> NIH awards Third Rock startup up to $10M for Fragile X work. Item
> Buzz: Hungry AstraZeneca circles a blockbuster biosimilars buyout. Report
> Cubist splurges on Trius and Optimer buyouts to spur antibiotics growth. Article
> Report: Alexion allies with Goldman as Roche buyout rumor blazes. More
Pharma News
@FiercePharma: ICYMI yesterday: Pfizer unit pleads guilty, agrees to pay $491M in off-label marketing case. Report | Follow @FiercePharma
@CarlyHFierce: Rumors swirling about an AstraZeneca Celltrion buyout, but the Korean co. says nothing is definite. Celltrion's statement | Follow @CarlyHFierce
> FDA clears Merck's Januvia, sister meds of new pancreatitis worries. Story
> Sanofi swaps leaders at animal health unit Merial. Item
> Bayer's new drugs shine, fueling 5.5% pharma growth. Article
Drug Delivery News
@MichaelGFierce: Swedish team creates 'impossible' record-breaking drug delivery material. More | Follow @MichaelGFierce
> Mallinckrodt, Depomed win priority review for oral pain med. Report
> Aussie method makes for smaller, more efficient inhaled drugs. More
> DNA-based molecular robots zero in on cancer, autoimmune diseases. Article
> Mercator snags FDA patent for blood-pressure drug delivery catheters. Item